CardiAQ Valve Technologies (CVT), a developer of self-conforming and self-anchoring technology for Transcatheter Mitral Valve Implantation (TMVI) is planning to present in vivo results of its Phase 1 porcine model study.
CVT said that the study has clearly demonstrated the capability of its proprietary transcatheter delivery system to successfully and repeatedly deliver a mitral valve implant.
CVT president and CEO Brent Ratz said that these latest in vivo results demonstrate that true transcatheter mitral valve implantation is not only achievable but also repeatable.
“We believe this is the first time anyone has successfully and repeatedly delivered and deployed a mitral valve through a transvenous, transseptal, catheter-based approach,” Ratz said.
“Our team continues to make significant technical progress against planned milestones. We will shortly execute the next phases of pre-clinical testing in preparation for a first-in-man trial of our TMVI technology in 2011.”
CVT co-founder, chairman and chief medical officer Arshad Quadri said that there remains an enormous unmet clinical need for the overwhelming majority of patients who suffer from mitral regurgitation.
“The fact is that a large majority of these patients suffer from functional MR and are too sick to undergo heart valve surgery. We believe that the applicability and efficacy of current transcatheter repair technologies are limited and that transcatheter mitral valve replacement will provide more effective treatment of MR to a wider range of patients,” Quadri said.